A clinical study of EO2463 for the treatment of B-cell malignancies (lymphomas and leukaemias)
Latest Information Update: 29 Jun 2020
At a glance
- Drugs EO 2463 (Primary)
- Indications B-cell leukaemia; B-cell lymphoma
- Focus Adverse reactions
Most Recent Events
- 29 Jun 2020 New trial record
- 25 Jun 2020 According to an Enterome media release, this study is expected to begin in 2021.